What is troglitazone?

The

Thiazolidion (TZD) of the drug class, intended for troglitazone, also known as Rezulin®, Resulin and Romozin ™, was to serve as an anti-diabetic drug and drugs were introduced in the late 1990s, which was introduced in the late 1990s. As an oral tablet, which starts with a meal of 200 milligrams and increased doses by 100-200 milligrams, as needed 100-200 milligrams appeared. Co., Ltd. The drug has achieved mainstream production in the United States via Pare-Davis after approved by the US food and drug administration (FDA) in January 1997. Before the approval of John Gueriguian, FDA Medicaldro-Lower Lower Lower Lower Lower Lower Lower Lower. PPAR attracts ligands from free fatty acids and eicosanoids, which are signaling molecules created by oxidation of 20-ulikal essential fatty acids (EFA). EFA is controlled by EFA. EiKosanoids are pro-inflammatory and are found in Omega-3 and Omega-6 fatty acids. EFA level changes in the body of a person can affect the functions they control.

PPAR is a group of proteins of nuclear receptors that act as transcription factors for regulating gene expression. Cell differentiation and development, as well as metabolic functioncens, are greatly affected by PPAR. However, when they focus on PPARS and other TZD drugs, they have not only found that they not only increase the toxicity of the liver, but their ability to inhibit the immune system can cause an idiosyncratic reaction that leads to hepatitis induced by drug.

The United Kingdom withdrew Troglitazone from its market in December 1997 after its adverse effects on the liver became known. In 2000, the US cleaned the drug from its market and soon after the Philippines, Australia and Japan followed. Although it has been shown that troglitazone reduces inflammation, has been found much wmore coded effects of the drug. Parke-Davis voluntarily stopped the production of drugs 21 March 2000.